Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Derace L. Schaffer sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $17.50, for a total value of $262,500.00. Following the completion of the transaction, the director now owns 48,730 shares in the company, valued at approximately $852,775. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) traded up 1.46% during trading on Thursday, reaching $17.40. The company had a trading volume of 480,800 shares. Lantheus Holdings, Inc. has a 12 month low of $7.61 and a 12 month high of $17.65. The firm’s 50 day moving average price is $17.19 and its 200 day moving average price is $14.98. The firm has a market capitalization of $649.89 million, a P/E ratio of 23.77 and a beta of 0.94.

Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.18. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The firm had revenue of $88.83 million for the quarter, compared to analyst estimates of $80.56 million. During the same quarter in the prior year, the company earned $0.24 EPS. Lantheus Holdings’s revenue was up 13.9% on a year-over-year basis. Equities analysts predict that Lantheus Holdings, Inc. will post $1.12 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/14/derace-l-schaffer-sells-15000-shares-of-lantheus-holdings-inc-lnth-stock.html.

Hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new stake in Lantheus Holdings in the 2nd quarter valued at approximately $102,000. Municipal Employees Retirement System of Michigan purchased a new stake in Lantheus Holdings in the 2nd quarter valued at approximately $107,000. LS Investment Advisors LLC purchased a new stake in Lantheus Holdings in the 2nd quarter valued at approximately $112,000. Quantbot Technologies LP purchased a new stake in Lantheus Holdings in the 2nd quarter valued at approximately $117,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in Lantheus Holdings in the 2nd quarter valued at approximately $141,000. 84.35% of the stock is currently owned by hedge funds and other institutional investors.

LNTH has been the topic of several research reports. Jefferies Group LLC restated a “buy” rating and issued a $18.00 target price on shares of Lantheus Holdings in a research report on Friday, June 30th. Zacks Investment Research downgraded Lantheus Holdings from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Cantor Fitzgerald initiated coverage on Lantheus Holdings in a research report on Monday, July 17th. They issued an “overweight” rating and a $22.00 target price on the stock. Credit Suisse Group raised their target price on Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Finally, BidaskClub downgraded Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 17th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Lantheus Holdings presently has an average rating of “Buy” and an average price target of $18.60.

About Lantheus Holdings

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Insider Buying and Selling by Quarter for Lantheus Holdings (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.